GlassScriptPhysician profile
Milan Chakrabarty
NPI 1700803798
$9,052.61
in general payments reported to CMS, 2019-2025
29 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $674 · 2021: $1,679 · 2022: $1,805 · 2023: $944 · 2024: $1,162 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,800.69 | 2019-2025 | Mavyret, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,027.26 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $734.63 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $623.51 | 2019-2025 | Entyvio |
| Redhill Biopharma INC. | $559.65 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Madrigal Pharmaceuticals | $452.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $356.31 | 2019-2025 | |
| Pfizer INC. | $191.16 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $140.40 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $138.72 | 2020-2023 | Linzess |
| Janssen Biotech, INC. | $138.54 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Endogastric Solutions, INC | $125.69 | 2022 | |
| Allergan, INC. | $113.04 | 2019-2020 | |
| Ucb, INC. | $95.49 | 2019 | |
| Vyaire Medical, INC. | $78.73 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $74.77 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $60.66 | 2021-2024 | |
| Vivus LLC | $45.03 | 2024 | Qsymia |
| Evoke Pharma, INC. | $42.81 | 2024 | |
| Merck Sharp & Dohme LLC | $42.00 | 2020-2023 | Dificid |
| Qol Medical, LLC | $37.58 | 2025 | Sucraid |
| Alnylam Pharmaceuticals INC. | $29.50 | 2024 | Oxlumo |
| Daiichi Sankyo INC. | $26.04 | 2024 | Injectafer |
| Echosens North America, INC. | $24.91 | 2025 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $23.62 | 2020 | |
| Boston Scientific Corporation | $21.97 | 2019 | |
| Novo Nordisk INC | $17.75 | 2025 | Wegovy |
| Enterra Medical, INC. | $15.97 | 2025 | |
| Concordia Pharmaceuticals INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Chakrabarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.